What Avant Technologies does

Avant Technologies is a healthcare technology company operating two parallel platforms: an AI-driven diagnostics platform branded VisionAI and a portfolio of cell-based therapies built around the licensed Cell-in-a-Box® microencapsulation technology. VisionAI applies computer vision and predictive analytics to retinal camera imagery to detect multiple conditions — diabetic retinopathy, cardiovascular disease, chronic kidney disease, liver fibrosis, type 2 diabetes, lung abnormalities, and early-stage dementia — with algorithms validated against over 2.3 million data points through a strategic collaboration with Apollo Hospitals in India. The cell-therapy pipeline targets type 1 and insulin-dependent type 2 diabetes through the Insulinova joint venture with SGAustria (reporting an 83% insulin independence rate in recent clinical trials) and age-related diseases through the Klothonova joint venture with Austrianova using α-Klotho protein overexpression. The company's revenue model is licensing- and royalty-based, executed through joint venture entities rather than direct sales: Ai-nova Acquisition Corp. (with Ainnova Tech) holds global commercialization rights for VisionAI, while Insulinova and Klothonova hold development and commercialization rights for their respective therapies; additional revenue capability comes from AI-driven healthcare data interoperability services inherited via the April 2024 acquisition of Wired-4-Health. No public pricing is disclosed. The company is pre-commercial or early-commercial: active clinical deployments exist in Chile, Dominican Republic, and Mexico, planned entry into Brazil is contingent on ANVISA approval, and U.S. market entry for VisionAI is contingent on FDA 510(k) clearance (pre-submission meeting completed May 2025). In April 2026, Tech Mahindra announced acquisition of an 85% stake in the Canada-incorporated Avant Technologies entity for CAD 28 million (with the remaining 15% to follow), a transaction primarily motivated by Tech Mahindra's BFSI ambitions rather than the healthcare pipeline itself. Note: the financial metrics block in the input data (revenue in the hundreds of billions, EV in the tens of trillions) is internally inconsistent with the firmographic profile (1-10 employees, private, founded 2019, CAD 28 million acquisition price) and is not used in this analysis.

Name

Avant Technologies

Legal name

Avant Technologies Inc.

Website

https://avanttechnologies.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Avant Technologies is a healthcare technology company developing AI-driven retinal diagnostics (VisionAI) for early multi-disease detection and proprietary cell-based therapies for diabetes and age-related diseases through joint ventures with Ainnova Tech, SGAustria, and Austrianova.

Ownership category

akta.pro rank

Product category

AI Medical Diagnostics Software

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Ophthalmic Goods Manufacturing (339115), Offices of Optometrists (62132), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851)

akta.pro primary industry

Medical Imaging AI (HDAAAEAH)

akta.pro secondary industries

Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ), Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB), Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging) (HLAFAKAI)

Keywords

• AI medical diagnostics
• Cell encapsulation therapy
• Diabetic retinopathy screening
• Regenerative medicine therapeutics
• Healthcare data interoperability

Headquarters

HQ city

Las Vegas

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. AI Diagnostics Platform Licensing: Commercialization of the VisionAI platform for early disease detection through licensing and commercialization rights held by Ai-nova Acquisition Corp., targeting healthcare providers, opticians, and eye care centers in North America, Europe, and Latin America.
2. Cell-Based Therapy Development and Commercialization: Development of cell encapsulation therapies for diabetes and age-related diseases through joint ventures (Insulinova for diabetes, Klothonova for α-Klotho), targeting global markets for type 1 and insulin-dependent type 2 diabetes treatments and anti-aging therapies.
3. Healthcare Data Interoperability Services: AI-driven data interoperability and computational capabilities in healthcare supporting improved outcomes and cost efficiencies, gained through the acquisition of Wired-4-Health.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels4 records

Core offering

Avant Technologies commercializes the VisionAI AI-driven diagnostic platform for early detection of multiple diseases via retinal image analysis, and develops proprietary cell-based therapies using Cell-in-a-Box® encapsulation technology for diabetes and age-related conditions. Offerings are delivered through joint ventures (Ai-nova Acquisition Corp., Insulinova, Klothonova) and targeted at healthcare providers, hospitals, opticians, and eye-care centers.

Differentiator

Problem solved

Functional benefit

Products and services

• VisionAI Platform AI-driven diagnostic platform that analyzes retinal camera images using computer vision and predictive analytics to detect multiple diseases early, including diabetic retinopathy, cardiovascular disease, chronic kidney disease, liver fibrosis, type 2 diabetes, and lung abnormalities. Algorithms are validated with over 2.3 million data points and the platform is under FDA 510(k) review for diabetic retinopathy screening. Sold to healthcare providers, opticians, and eye care centers.

Quantifiable outcome

• 83% insulin independence rate in recent clinical trials for diabetes cell therapies
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• SGAustria Pte. Ltd.coreStrategic or Co-development Partner · 4 November 2025Joint venture Insulinova, Inc. formed between Avant Technologies and SGAustria to develop a stem cell-based diabetes treatment. The partnership combines SGAustria's Cell-in-a-Box® cell encapsulation technology with Avant's funding and development efforts to create scalable solutions for type 1 and insulin-dependent type 2 diabetes globally.
• AustrianovacoreStrategic or Co-development Partner · 22 October 2025Joint venture Klothonova LLC launched by Avant Technologies and Austrianova to develop cellular therapies using the 'Longevity Protein' Klotho to combat age-related diseases. The program has demonstrated proof of concept with encapsulated cells overproducing Klotho and is moving toward preclinical and clinical studies using Austrianova's cell-encapsulation technology.
• Apollo HospitalscoreStrategic or Co-development Partner · 10 March 2025Strategic collaboration with Apollo Hospitals to deploy AI algorithms for early detection of cardiovascular disease, chronic kidney disease, liver fibrosis, type 2 diabetes, and lung abnormalities. Avant holds an exclusive license for AI algorithms validated with over 2.3 million data points, with commercial pilot programs launching across the Americas and planned expansion to Brazil.
• Ainnova Tech, Inc.coreStrategic or Co-development Partner · 12 November 2024Avant Technologies and Ainnova Tech formed a joint venture through Ai-nova Acquisition Corp to commercialize Ainnova's VisionAI platform and retinal camera technology for early disease detection across North America and Europe. Avant's capital investment scales AI-powered diagnostic solutions including diabetic retinopathy screening and cardiovascular risk assessment.
• Wired-4-HealthcoreTechnology or Integration · 9 April 2024Avant Technologies completed its acquisition of Wired-4-Health, a healthcare technology and data integration services firm, on April 9, 2024. The merger aims to enhance AI-driven data interoperability and computational capabilities in healthcare, supporting improved outcomes and cost efficiencies.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Eyenuk: AI platform for eye disease screening including diabetic retinopathy (EyeArt), FDA-cleared. Directly competes in the same AI retinal screening category and primary care/eye care deployment model.
• Digital Diagnostics: FDA-cleared autonomous AI for diabetic retinopathy screening (IDx-DR). Closest US-market comparable to Avant's VisionAI diabetic retinopathy indication, competing for the same ophthalmology and primary care screening channels.
• AEYE Health: AI-based retinal screening for diabetic retinopathy with FDA clearance. Direct peer in the autonomous AI diagnostic category targeting similar primary care and optometry deployment.
• Sernova Corp: Cell therapy company developing Cell Pouch system for insulin-dependent diabetes. Closest peer to Avant's Insulinova program in encapsulated cell-based diabetes treatment.
• Ainnova Tech: AI-driven retinal imaging diagnostics company; Avant's joint venture partner for VisionAI commercialization. Directly comparable as the originator of the core AI screening technology Avant distributes.
• ViaCyte (now part of Vertex): Stem cell-derived islet cell therapy for type 1 diabetes, recently acquired by Vertex. Directly comparable to Insulinova's stem cell-based diabetes approach with similar clinical-stage asset.

Emerging players

• Sigilon Therapeutics: Encapsulated cell therapies for type 1 diabetes and rare diseases using Afibromer technology. Comparable in the encapsulated live-cell therapy category targeting diabetes.

Broad incumbents

• Tempus AI: AI-driven precision medicine platform with broad diagnostics, multi-omics, and clinical decision support offerings. Comparable as a broader healthcare AI/diagnostics incumbent pursuing multi-condition clinical AI.
• Google Health (Verily/Google DeepMind): Major tech incumbent developing AI for medical imaging and diagnostics including retinal screening. Competes at the platform level for healthcare AI talent, datasets, and clinical partnerships.

Others

• Austrianova: Cell encapsulation technology provider and Avant's JV partner for Klothonova. Adjacent enabler rather than competitor; provides the underlying Cell-in-a-Box encapsulation platform Avant licenses for therapeutic programs.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/AvantTechAI
• Facebookfacebook.com/AvantTechAI
• LinkedInlinkedin.com/company/avant-technologies-ai

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avant Technologies